Three ‐year risk of high‐grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co‐screening

CONCLUSIONSPap cytology and HPV cotesting are valuable for stratifying CIN‐3 risk. Pap cytology and HPV co‐screening at a 3‐year screening interval appears to carry a low risk of CIN‐3 for women who have a baseline Pap‐/HPV‐ cotesting result. Cancer (Cancer Cytopathol) 2017. © 2017 American Cancer Society.

Source: Cancer Cytopathology - April 1, 2017 Category: Pathology Authors: Ming Guo, Abha Khanna, Jianping Wang, Marilyn A. Dawlett, Teresa L. Kologinczak, Genevieve R. Lyons, Roland L. Bassett, Nour Sneige, Yun Gong, Therese B. Bevers Tags: Original Article Source Type: research